A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants

被引：49

作者：

Nolan, Terry ^{[1
,2
]}

Lambert, Stephen ^{[1
,2
]}

Roberton, Don ^{[3
,4
]}

Marshall, Helen ^{[3
,4
]}

Richmond, Peter ^{[5
]}

Streeton, Catherine ^{[6
]}

Poolman, Jan ^{[7
]}

Boutriau, Dominique ^{[7
]}

机构：

[1] Univ Melbourne, Murdoch Childrens Res Inst, Carlton, Vic 3010, Australia

[2] Univ Melbourne, Sch Populat Hlth, Carlton, Vic 3010, Australia

[3] Univ Adelaide, Sch Paediat & Reprod Hlth, Adelaide, SA, Australia

[4] Womens & Childrens Hosp, Paediat Trials Unit, Dept Paediat, Adelaide, SA, Australia

[5] Univ Western Australia, Sch Pediat & Child Hlth, Princess Margaret Hosp Children, Nedlands, WA 6009, Australia

[6] GlaxoSmithKline, Melbourne, Vic, Australia

[7] GlaxoSmithKline Biol, Rixensart, Belgium

来源：

VACCINE | 2007年 / 25卷 / 51期

关键词：

Neisseria meningitidis serogroup C; Neisseria meningitidis serogroup Y; vaccine;

D O I：

10.1016/j.vaccine.2007.10.013

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immunogenicity and safety of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine (Hib-MenCY-TT) candidate was evaluated when co-administered with DTPa-HBV-IPV(Pediarix(TM3)) + PCV7(Prevnar(TM4)) at 2-4-6 months of age. Anti-PRP concentrations >= 1.0 mu g/mL were observed in 92.9-98.7%, rSBA-MenC/Y titres >= 1:8 in >98%, rSBA-MenC/Y titres >= 1:128 in >95.8 and >89.9% subjects. PRP and MenC responses were similar to respective controls (ActHIB(TM5) and Menjugate(TM6)) including for antibody persistence. Response to co-administered vaccines was not impaired. Polysaccharide challenge (PRP, PSC, PSY at 11-14 months of age) evidenced immune memory was induced for Hib, MenC/Y conjugate components. The safety profile of Hib-MenCY-TT was similar to controls. Hib-MenCY-TT administered according to the current US Hib vaccine schedule has the potential to induce protective antibodies against Hib and meningococcal-CY disease in infants and toddlers. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：8487 / 8499

页数：13

共 32 条

[21]

NETO VA, 1974, REV INST MED TROP SP, V16, P149

[22]

POLLARD AJ, 2004, ANNU REV MED, V55, P333

[23]

Pollard Andrew J, 2004, Pediatr Infect Dis J, V23, pS274

[24] ASSIGNMENT OF WEIGHT-BASED ANTIBODY UNITS TO A HUMAN ANTIPNEUMOCOCCAL STANDARD REFERENCE SERUM, LOT 89-S [J].